James Miller
Concepts (325)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 44 | 2020 | 2568 | 2.500 |
Why?
| | Smoking | 20 | 2019 | 1579 | 1.190 |
Why?
| | Bronchi | 13 | 2018 | 263 | 1.150 |
Why?
| | Carcinoma in Situ | 5 | 2019 | 44 | 1.050 |
Why?
| | Carcinoma, Squamous Cell | 10 | 2018 | 643 | 0.730 |
Why?
| | Carcinogens | 4 | 2012 | 125 | 0.720 |
Why?
| | Chemoprevention | 3 | 2019 | 95 | 0.690 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2012 | 83 | 0.690 |
Why?
| | Lung | 16 | 2020 | 4078 | 0.570 |
Why?
| | Carcinoma, Small Cell | 7 | 2008 | 171 | 0.470 |
Why?
| | Bronchoscopy | 9 | 2019 | 227 | 0.470 |
Why?
| | Urethane | 3 | 2012 | 43 | 0.460 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 2019 | 406 | 0.440 |
Why?
| | Sputum | 8 | 2019 | 311 | 0.440 |
Why?
| | Pulmonary Alveoli | 4 | 2012 | 392 | 0.440 |
Why?
| | Iloprost | 2 | 2012 | 44 | 0.440 |
Why?
| | Hyperplasia | 7 | 2011 | 174 | 0.430 |
Why?
| | Precancerous Conditions | 7 | 2020 | 165 | 0.420 |
Why?
| | Neprilysin | 3 | 1998 | 45 | 0.400 |
Why?
| | Quinazolines | 2 | 2012 | 260 | 0.370 |
Why?
| | Biopsy | 11 | 2019 | 1081 | 0.370 |
Why?
| | Piperidines | 2 | 2012 | 220 | 0.370 |
Why?
| | Biomarkers, Tumor | 7 | 2015 | 1262 | 0.370 |
Why?
| | Antineoplastic Agents | 4 | 2013 | 2167 | 0.360 |
Why?
| | DNA Copy Number Variations | 1 | 2011 | 182 | 0.330 |
Why?
| | Bombesin | 5 | 1998 | 11 | 0.330 |
Why?
| | Genetic Markers | 1 | 2011 | 343 | 0.330 |
Why?
| | Amidohydrolases | 3 | 1998 | 32 | 0.320 |
Why?
| | Neurosecretory Systems | 4 | 2004 | 31 | 0.310 |
Why?
| | Isotretinoin | 1 | 2009 | 24 | 0.300 |
Why?
| | Ki-67 Antigen | 3 | 2015 | 111 | 0.300 |
Why?
| | Tocopherols | 1 | 2009 | 26 | 0.300 |
Why?
| | Vasodilator Agents | 1 | 2011 | 330 | 0.300 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 7 | 2013 | 1128 | 0.300 |
Why?
| | ErbB Receptors | 1 | 2012 | 615 | 0.290 |
Why?
| | Neovascularization, Pathologic | 6 | 2015 | 295 | 0.270 |
Why?
| | Membrane Proteins | 2 | 2008 | 1160 | 0.270 |
Why?
| | Mass Screening | 3 | 2008 | 1325 | 0.270 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2018 | 1045 | 0.270 |
Why?
| | Respiratory Mucosa | 2 | 2008 | 324 | 0.250 |
Why?
| | Adenocarcinoma | 6 | 2012 | 904 | 0.230 |
Why?
| | Hypoxia | 1 | 2012 | 1166 | 0.220 |
Why?
| | Chromosomes, Human, Pair 3 | 4 | 2000 | 46 | 0.210 |
Why?
| | Carcinoma, Bronchogenic | 2 | 2002 | 20 | 0.200 |
Why?
| | Chromosome Aberrations | 4 | 2013 | 161 | 0.200 |
Why?
| | Tomography, Spiral Computed | 1 | 2002 | 32 | 0.190 |
Why?
| | Middle Aged | 28 | 2019 | 35049 | 0.190 |
Why?
| | Aged | 25 | 2019 | 25117 | 0.190 |
Why?
| | Humans | 53 | 2020 | 142526 | 0.180 |
Why?
| | Sensitivity and Specificity | 10 | 2010 | 1977 | 0.170 |
Why?
| | Smokers | 2 | 2019 | 146 | 0.170 |
Why?
| | Placebos | 2 | 2019 | 195 | 0.170 |
Why?
| | Female | 33 | 2019 | 76624 | 0.170 |
Why?
| | Lung Diseases | 5 | 2015 | 786 | 0.170 |
Why?
| | Double-Blind Method | 2 | 2019 | 2007 | 0.170 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2012 | 114 | 0.160 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2771 | 0.160 |
Why?
| | Neuropeptides | 4 | 1998 | 77 | 0.150 |
Why?
| | Tumor Cells, Cultured | 6 | 1998 | 960 | 0.150 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 119 | 0.150 |
Why?
| | Male | 30 | 2019 | 70910 | 0.150 |
Why?
| | Remission Induction | 1 | 2019 | 306 | 0.140 |
Why?
| | In Situ Hybridization, Fluorescence | 6 | 2010 | 310 | 0.140 |
Why?
| | Peptides | 3 | 1996 | 974 | 0.140 |
Why?
| | Blotting, Western | 4 | 2012 | 1220 | 0.140 |
Why?
| | Genes, p53 | 1 | 1997 | 68 | 0.130 |
Why?
| | Lung Diseases, Obstructive | 1 | 1997 | 43 | 0.130 |
Why?
| | Immunohistochemistry | 8 | 2015 | 1727 | 0.130 |
Why?
| | Point Mutation | 1 | 1997 | 240 | 0.130 |
Why?
| | Antibodies, Monoclonal | 3 | 2010 | 1471 | 0.120 |
Why?
| | Radiation Injuries, Experimental | 1 | 1996 | 21 | 0.120 |
Why?
| | Proteomics | 2 | 2015 | 1152 | 0.120 |
Why?
| | Bradykinin | 1 | 1996 | 48 | 0.120 |
Why?
| | Endopeptidases | 1 | 1996 | 81 | 0.120 |
Why?
| | Chromosomal Instability | 2 | 2013 | 21 | 0.120 |
Why?
| | Smoking Cessation | 1 | 2019 | 434 | 0.110 |
Why?
| | Hyperoxia | 1 | 1996 | 92 | 0.110 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2015 | 21 | 0.110 |
Why?
| | Mice | 10 | 2012 | 18172 | 0.110 |
Why?
| | Animals | 13 | 2013 | 37697 | 0.110 |
Why?
| | Gene Expression | 3 | 1998 | 1496 | 0.110 |
Why?
| | Methylcholanthrene | 2 | 2012 | 21 | 0.110 |
Why?
| | Butylated Hydroxytoluene | 2 | 2012 | 36 | 0.100 |
Why?
| | Antigens | 1 | 1996 | 349 | 0.100 |
Why?
| | Mice, Transgenic | 5 | 2009 | 2180 | 0.100 |
Why?
| | Risk Factors | 5 | 2019 | 10593 | 0.100 |
Why?
| | Microarray Analysis | 1 | 2013 | 117 | 0.100 |
Why?
| | Stem Cells | 1 | 2018 | 612 | 0.100 |
Why?
| | Mutation | 4 | 2000 | 4024 | 0.100 |
Why?
| | Algorithms | 3 | 2020 | 1791 | 0.100 |
Why?
| | Epithelium | 4 | 2018 | 313 | 0.100 |
Why?
| | Intramolecular Oxidoreductases | 2 | 2004 | 66 | 0.100 |
Why?
| | Aged, 80 and over | 8 | 2015 | 8020 | 0.100 |
Why?
| | Risk | 5 | 2012 | 905 | 0.100 |
Why?
| | Carcinoma, Large Cell | 1 | 2012 | 15 | 0.100 |
Why?
| | Biological Products | 1 | 1996 | 243 | 0.090 |
Why?
| | Epithelial Cells | 3 | 2007 | 1116 | 0.090 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2004 | 159 | 0.090 |
Why?
| | Receptors, Bombesin | 1 | 2012 | 2 | 0.090 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2002 | 636 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 206 | 0.090 |
Why?
| | Cell Division | 4 | 2000 | 794 | 0.090 |
Why?
| | Volatile Organic Compounds | 1 | 2012 | 63 | 0.090 |
Why?
| | Case-Control Studies | 8 | 2012 | 3604 | 0.090 |
Why?
| | Sleep Apnea Syndromes | 1 | 2012 | 90 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2010 | 2053 | 0.090 |
Why?
| | Chromosomes, Human, Pair 15 | 1 | 2011 | 53 | 0.080 |
Why?
| | Eosinophilic Granuloma | 1 | 1990 | 3 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2012 | 164 | 0.080 |
Why?
| | Veterans | 1 | 2002 | 1531 | 0.080 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2012 | 214 | 0.080 |
Why?
| | Antioxidants | 2 | 2012 | 594 | 0.080 |
Why?
| | Plants, Toxic | 1 | 1989 | 19 | 0.080 |
Why?
| | Cell Line | 5 | 2013 | 2878 | 0.080 |
Why?
| | Proteins | 1 | 1996 | 1013 | 0.080 |
Why?
| | Calcium | 1 | 1996 | 1179 | 0.080 |
Why?
| | Somatomedins | 1 | 2009 | 28 | 0.080 |
Why?
| | Genome-Wide Association Study | 2 | 2013 | 1426 | 0.080 |
Why?
| | Predictive Value of Tests | 4 | 2009 | 2081 | 0.080 |
Why?
| | Disease Progression | 5 | 2018 | 2831 | 0.070 |
Why?
| | Cell Proliferation | 2 | 2018 | 2514 | 0.070 |
Why?
| | Bronchial Neoplasms | 1 | 2009 | 15 | 0.070 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2011 | 469 | 0.070 |
Why?
| | Chromosome Deletion | 1 | 1989 | 118 | 0.070 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2009 | 50 | 0.070 |
Why?
| | Adult | 16 | 2018 | 39715 | 0.070 |
Why?
| | Respiratory System | 1 | 1989 | 156 | 0.070 |
Why?
| | GPI-Linked Proteins | 1 | 2008 | 78 | 0.070 |
Why?
| | Airway Obstruction | 3 | 2009 | 166 | 0.070 |
Why?
| | Neoplasm Invasiveness | 4 | 2015 | 512 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 622 | 0.070 |
Why?
| | Fluorescence | 3 | 2009 | 161 | 0.070 |
Why?
| | Alkaline Phosphatase | 1 | 2008 | 146 | 0.070 |
Why?
| | Spectral Karyotyping | 1 | 2007 | 5 | 0.070 |
Why?
| | Isoenzymes | 1 | 2008 | 296 | 0.070 |
Why?
| | Molecular Targeted Therapy | 1 | 2010 | 421 | 0.070 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2009 | 337 | 0.070 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2008 | 251 | 0.060 |
Why?
| | Molecular Sequence Data | 5 | 1998 | 2916 | 0.060 |
Why?
| | Pulmonary Surfactants | 2 | 1999 | 103 | 0.060 |
Why?
| | Inflammation | 1 | 2018 | 2867 | 0.060 |
Why?
| | Exons | 2 | 1998 | 352 | 0.060 |
Why?
| | Fibroblasts | 3 | 1998 | 1033 | 0.060 |
Why?
| | MicroRNAs | 1 | 2012 | 696 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2146 | 0.060 |
Why?
| | Follow-Up Studies | 2 | 2015 | 5270 | 0.060 |
Why?
| | Early Detection of Cancer | 1 | 2010 | 441 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2005 | 853 | 0.060 |
Why?
| | ROC Curve | 3 | 2015 | 600 | 0.060 |
Why?
| | Recombinant Proteins | 3 | 1998 | 1364 | 0.060 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 440 | 0.060 |
Why?
| | Biomarkers | 3 | 2010 | 4207 | 0.060 |
Why?
| | RNA, Messenger | 3 | 1998 | 2828 | 0.050 |
Why?
| | Polymerase Chain Reaction | 3 | 1998 | 1051 | 0.050 |
Why?
| | Growth Hormone-Releasing Hormone | 1 | 2004 | 25 | 0.050 |
Why?
| | Acromegaly | 1 | 2004 | 16 | 0.050 |
Why?
| | Cytokines | 1 | 2012 | 2093 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 1 | 2010 | 927 | 0.050 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2004 | 147 | 0.050 |
Why?
| | Rats | 4 | 2004 | 5585 | 0.050 |
Why?
| | Smoke | 1 | 2004 | 149 | 0.050 |
Why?
| | Base Sequence | 3 | 1998 | 2176 | 0.050 |
Why?
| | Solitary Pulmonary Nodule | 1 | 2002 | 21 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 1087 | 0.050 |
Why?
| | Metaplasia | 2 | 2018 | 58 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 547 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 5700 | 0.050 |
Why?
| | Sex Factors | 1 | 2007 | 2074 | 0.040 |
Why?
| | Hospitals, Veterans | 1 | 2002 | 255 | 0.040 |
Why?
| | Pulmonary Fibrosis | 2 | 1998 | 391 | 0.040 |
Why?
| | Radiation Dosage | 1 | 2002 | 192 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2008 | 3362 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 1989 | 2608 | 0.040 |
Why?
| | Amino Acid Sequence | 3 | 1994 | 2150 | 0.040 |
Why?
| | Cohort Studies | 4 | 2015 | 5858 | 0.040 |
Why?
| | Gastrin-Releasing Peptide | 2 | 1996 | 7 | 0.040 |
Why?
| | Autocrine Communication | 1 | 1998 | 40 | 0.040 |
Why?
| | Desmoglein 3 | 1 | 2018 | 14 | 0.040 |
Why?
| | gamma Catenin | 1 | 2018 | 13 | 0.040 |
Why?
| | Loss of Heterozygosity | 2 | 2013 | 51 | 0.040 |
Why?
| | Light | 1 | 2001 | 399 | 0.040 |
Why?
| | DNA Primers | 2 | 1998 | 507 | 0.040 |
Why?
| | Signal Transduction | 3 | 1998 | 5163 | 0.040 |
Why?
| | Up-Regulation | 2 | 2005 | 857 | 0.040 |
Why?
| | Bronchial Diseases | 1 | 2018 | 37 | 0.040 |
Why?
| | Paracrine Communication | 1 | 1998 | 67 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 1998 | 251 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2002 | 1047 | 0.030 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 1998 | 41 | 0.030 |
Why?
| | Time | 1 | 2018 | 87 | 0.030 |
Why?
| | Telangiectasia, Hereditary Hemorrhagic | 1 | 1998 | 14 | 0.030 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 1997 | 25 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2018 | 97 | 0.030 |
Why?
| | Genes, Tumor Suppressor | 1 | 1998 | 85 | 0.030 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 1998 | 91 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2005 | 1773 | 0.030 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1997 | 68 | 0.030 |
Why?
| | Likelihood Functions | 1 | 1998 | 143 | 0.030 |
Why?
| | DNA, Complementary | 1 | 1998 | 275 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 1998 | 270 | 0.030 |
Why?
| | Codon | 1 | 1997 | 92 | 0.030 |
Why?
| | Neoplasm Staging | 2 | 2012 | 1404 | 0.030 |
Why?
| | Introns | 1 | 1998 | 253 | 0.030 |
Why?
| | Mice, Nude | 1 | 1998 | 701 | 0.030 |
Why?
| | United States | 2 | 2011 | 15447 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 1999 | 496 | 0.030 |
Why?
| | Immunoassay | 2 | 1998 | 110 | 0.030 |
Why?
| | Enzyme Activation | 1 | 1998 | 785 | 0.030 |
Why?
| | Incidence | 3 | 2010 | 2826 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2011 | 11298 | 0.030 |
Why?
| | RNA, Neoplasm | 1 | 1996 | 80 | 0.030 |
Why?
| | Glycopeptides | 1 | 1996 | 44 | 0.030 |
Why?
| | Mesothelioma | 1 | 1996 | 46 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 771 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 1998 | 820 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 622 | 0.030 |
Why?
| | Antigens, CD | 2 | 1998 | 545 | 0.030 |
Why?
| | Receptors, Peptide | 1 | 1994 | 19 | 0.030 |
Why?
| | Machine Learning | 1 | 2020 | 567 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 634 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1458 | 0.030 |
Why?
| | Myelin Sheath | 1 | 1996 | 164 | 0.030 |
Why?
| | Rh-Hr Blood-Group System | 1 | 1994 | 14 | 0.030 |
Why?
| | Erythrocyte Membrane | 1 | 1994 | 52 | 0.030 |
Why?
| | Blotting, Southern | 1 | 1993 | 76 | 0.030 |
Why?
| | Blotting, Northern | 1 | 1993 | 200 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 1996 | 676 | 0.020 |
Why?
| | Prospective Studies | 3 | 2012 | 7862 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 1993 | 159 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2007 | 4167 | 0.020 |
Why?
| | Solid Phase Microextraction | 1 | 2012 | 9 | 0.020 |
Why?
| | Endoscopy | 1 | 2015 | 327 | 0.020 |
Why?
| | Dinoprostone | 2 | 2004 | 181 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 1993 | 381 | 0.020 |
Why?
| | Breath Tests | 1 | 2012 | 77 | 0.020 |
Why?
| | Cloning, Molecular | 1 | 1993 | 532 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2012 | 134 | 0.020 |
Why?
| | Colorado | 1 | 2002 | 4638 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 1996 | 837 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1453 | 0.020 |
Why?
| | Liver Neoplasms | 1 | 1998 | 755 | 0.020 |
Why?
| | Iceland | 1 | 2011 | 11 | 0.020 |
Why?
| | Tumor Suppressor p53-Binding Protein 1 | 1 | 2011 | 13 | 0.020 |
Why?
| | Spain | 1 | 2011 | 48 | 0.020 |
Why?
| | Netherlands | 1 | 2011 | 86 | 0.020 |
Why?
| | Respiratory Tract Diseases | 1 | 1992 | 180 | 0.020 |
Why?
| | Cattle | 1 | 1993 | 988 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 1996 | 2523 | 0.020 |
Why?
| | Administration, Oral | 1 | 2012 | 835 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2011 | 169 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2927 | 0.020 |
Why?
| | Carrier Proteins | 1 | 1994 | 743 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2009 | 64 | 0.020 |
Why?
| | Prognosis | 2 | 2012 | 4112 | 0.020 |
Why?
| | Flow Cytometry | 1 | 1993 | 1185 | 0.020 |
Why?
| | Area Under Curve | 1 | 2010 | 326 | 0.020 |
Why?
| | International Agencies | 1 | 2009 | 32 | 0.020 |
Why?
| | Cystic Fibrosis | 1 | 1998 | 1132 | 0.020 |
Why?
| | Erythrocytes | 1 | 1994 | 701 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2010 | 738 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1989 | 590 | 0.020 |
Why?
| | Genome, Human | 1 | 2009 | 425 | 0.020 |
Why?
| | Pilot Projects | 1 | 2012 | 1829 | 0.020 |
Why?
| | Models, Statistical | 1 | 2010 | 677 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1866 | 0.010 |
Why?
| | Amino Acids | 1 | 1989 | 505 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1996 | 4483 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 108 | 0.010 |
Why?
| | Genomics | 1 | 2009 | 820 | 0.010 |
Why?
| | Epoprostenol | 1 | 2004 | 131 | 0.010 |
Why?
| | Bronchiolitis | 1 | 2004 | 84 | 0.010 |
Why?
| | Autoantibodies | 1 | 2010 | 1482 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 985 | 0.010 |
Why?
| | Fruit | 1 | 2003 | 146 | 0.010 |
Why?
| | Vegetables | 1 | 2003 | 161 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 759 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 2004 | 559 | 0.010 |
Why?
| | Pituitary Neoplasms | 1 | 2004 | 195 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2011 | 2388 | 0.010 |
Why?
| | Adenoma | 1 | 2004 | 218 | 0.010 |
Why?
| | Regression Analysis | 1 | 2003 | 1013 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2001 | 290 | 0.010 |
Why?
| | Weight Gain | 1 | 2004 | 542 | 0.010 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2000 | 50 | 0.010 |
Why?
| | Carcinoma | 1 | 2001 | 230 | 0.010 |
Why?
| | Bronchoscopes | 1 | 1998 | 3 | 0.010 |
Why?
| | RNA | 1 | 2005 | 929 | 0.010 |
Why?
| | Endoglin | 1 | 1998 | 18 | 0.010 |
Why?
| | Random Allocation | 1 | 1998 | 370 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1998 | 288 | 0.010 |
Why?
| | Reference Values | 1 | 1998 | 807 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2015 | 16626 | 0.010 |
Why?
| | Comorbidity | 1 | 2001 | 1678 | 0.010 |
Why?
| | Linear Models | 1 | 1998 | 857 | 0.010 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2000 | 531 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2003 | 2980 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1998 | 1313 | 0.010 |
Why?
| | Receptors, Cell Surface | 1 | 1998 | 376 | 0.010 |
Why?
| | Diet | 1 | 2003 | 1284 | 0.010 |
Why?
| | Alleles | 1 | 1998 | 885 | 0.010 |
Why?
| | Risk Assessment | 1 | 2004 | 3562 | 0.010 |
Why?
| | Chromatography, Affinity | 1 | 1994 | 85 | 0.010 |
Why?
| | Infant, Premature | 1 | 1998 | 604 | 0.010 |
Why?
| | Young Adult | 1 | 2011 | 13878 | 0.010 |
Why?
| | CD47 Antigen | 1 | 1994 | 43 | 0.010 |
Why?
| | Genes | 1 | 1994 | 229 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 333 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2000 | 951 | 0.010 |
Why?
| | Moths | 1 | 1994 | 53 | 0.010 |
Why?
| | Cytoplasm | 1 | 1994 | 267 | 0.010 |
Why?
| | Carcinoid Tumor | 1 | 1992 | 22 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1994 | 502 | 0.010 |
Why?
| | Transfection | 1 | 1994 | 936 | 0.010 |
Why?
| | Lymphocytes | 1 | 1994 | 395 | 0.010 |
Why?
| | Adolescent | 1 | 2011 | 22326 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 1994 | 1267 | 0.010 |
Why?
| | Dyspnea | 1 | 1992 | 259 | 0.010 |
Why?
| | Binding Sites | 1 | 1994 | 1317 | 0.010 |
Why?
| | Fibrosis | 1 | 1992 | 545 | 0.000 |
Why?
| | Phenotype | 1 | 1998 | 3184 | 0.000 |
Why?
| | Aging | 1 | 1998 | 1931 | 0.000 |
Why?
| | Infant, Newborn | 1 | 1998 | 6324 | 0.000 |
Why?
| | Infant | 1 | 1998 | 9908 | 0.000 |
Why?
| | Child, Preschool | 1 | 1998 | 11634 | 0.000 |
Why?
| | Child | 1 | 1998 | 22562 | 0.000 |
Why?
|
|
Miller's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|